Gene expression anti-profiles as a basis for accurate universal cancer signatures

BMC Bioinformatics

Volumn 13, Issue 1, 2012, Pages

  Corrada Bravo, Héctor ^a   Pihur, Vasyl ^b   McCall, Matthew ^c   Irizarry, Rafael A ^b   Leek, Jeffrey T ^b  

^a University of Maryland ^*  (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Anti profiles; Cancer; Gene expression; Genomic signatures; Microarray normalization and quality assessment

Indexed keywords

ANTI-PROFILES; CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL SETTINGS; COLON CANCER; COMPUTATIONAL PREDICTIONS; CROSS VALIDATION; GENOMIC SIGNATURES; HIGHLY ACCURATE; NEW APPROACHES; PERIPHERAL BLOOD; QUALITY ASSESSMENT; SCREENING TESTS; SINGLE-CHIP; TISSUE BIOPSIES; TISSUE SAMPLES; TISSUE TYPES; TISSUE-SPECIFIC GENES;

BLOOD; GENE EXPRESSION; TISSUE;

DISEASES;

TRANSCRIPTOME; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BLOOD; COLON TUMOR; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENETICS; GENOMICS; HUMAN; METHODOLOGY; PROGNOSIS;

AREA UNDER CURVE; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENOMICS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84867637986     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-13-272     Document Type: Article

References (53)

1. Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, Nagengast FM, Menko FH, Meera Khan P. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998, 82(9):1632-1637. 10.1002/(SICI)1097-0142(19980501)82:9<1632::AID-CNCR6>3.0.CO;2-C, 9576281.
2. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, de Haes JC, Collette HJ, Hendriks JH, van der Maas PJ. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991, 49(4):531-537. 10.1002/ijc.2910490410, 1917154.
3. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005, 353(20):2158-2168. 10.1056/NEJMsa044278, 16291985.
4. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003, 57(1):23-29.
5. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, Ljungquist U, Lundstrom B, Manson JC, Eklund G, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985, 1(8433):829-832.
6. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993, 341(8851):973-978. 10.1016/0140-6736(93)91067-V, 8096941.
7. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992, 84(20):1572-1575. 10.1093/jnci/84.20.1572, 1404450.
8. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13):1310-1319. 10.1056/NEJMoa0810696, 2944770, 19297565.
9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993, 328(19):1365-1371.
10. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 2003, 289(10):1288-1296. 10.1001/jama.289.10.1288, 12633191.
11. Klabunde CN, Vernon SW, Nadel MR, Breen N, Seeff LC, Brown ML. Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. Med Care 2005, 43(9):939-944. 10.1097/01.mlr.0000173599.67470.ba, 16116360.
12. Lerman C, Rimer B, Trock B, Balshem A, Engstrom PF. Factors associated with repeat adherence to breast cancer screening. Prev Med 1990, 19(3):279-290. 10.1016/0091-7435(90)90028-I, 2377590.
13. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003, 97(6):1528-1540. 10.1002/cncr.11208, 12627518.
14. Harewood GC, Wiersema MJ, Melton LJ. A prospective, controlled assessment of factors influencing acceptance of screening colonoscopy. Am J Gastroenterol 2002, 97(12):3186-3194. 10.1111/j.1572-0241.2002.07129.x, 12492209.
15. Furukawa H. Diagnostic clues for early pancreatic cancer. Jpn J Clin Oncol 2002, 32(10):391-392. 10.1093/jjco/hyf099, 12451033.
16. Bach PB, Silvestri GA, Hanger M, Jett JR. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl):69S-77S.
17. Sheng J, Zhang WY. Identification biomarkers for cervical cancer in peripheral blood lymphocytes by oligonucleotide microarrays. Zhonghua Yi Xue Za Zhi 2010, 90(37):2611-2615.
18. Aaroe J, Lindahl T, Dumeaux V, Saebo S, Tobin D, Hagen N, Skaane P, Lonneborg A, Sharma P, Borresen-Dale AL. Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res 2010, 12(1):R7. 10.1186/bcr2472, 2880427, 20078854.
19. Han M, Liew CT, Zhang HW, Chao S, Zheng R, Yip KT, Song ZY, Li HM, Geng XP, Zhu LX, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res 2008, 14(2):455-460. 10.1158/1078-0432.CCR-07-1801, 18203981.
20. Zander T, Hofmann A, Staratschek-Jox A, Classen S, Debey-Pascher S, Maisel D, Ansen S, Hahn M, Beyer M, Thomas RK, et al. Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res 2011, 17(10):3360-3367. 10.1158/1078-0432.CCR-10-0533, 21558400.
21. Osman I, Bajorin DF, Sun TT, Zhong H, Douglas D, Scattergood J, Zheng R, Han M, Marshall KW, Liew CC. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res 2006, 12(11 Pt 1):3374-3380.
22. Feinberg AP, Irizarry RA. Evolution in health and medicine Sackler colloquium: Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc Natl Acad Sci USA 2010, 107(Suppl 1):1757-1764. 2868296, 20080672.
23. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, Wen B, Wu H, Liu Y, Diep D, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011, 43(8):768-775. 10.1038/ng.865, 3145050, 21706001.
24. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009, 41(2):178-186. 10.1038/ng.298, 2729128, 19151715.
25. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 2008, 105(51):20422-20427. 10.1073/pnas.0810777105, 2603434, 19088187.
26. Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, Akey JM. Gene-expression variation within and among human populations. Am J Hum Genet 2007, 80(3):502-509. 10.1086/512017, 1821107, 17273971.
27. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, et al. Population genomics of human gene expression. Nat Genet 2007, 39(10):1217-1224. 10.1038/ng2142, 2683249, 17873874.
28. Jimenez-Gomez JM, Corwin JA, Joseph B, Maloof JN, Kliebenstein DJ. Genomic Analysis of QTLs and Genes Altering Natural Variation in Stochastic Noise. PLoS Genet 2011, 7(9):e1002295. 10.1371/journal.pgen.1002295, 3183082, 21980300.
29. Li J, Liu Y, Kim T, Min R, Zhang Z. Gene expression variability within and between human populations and implications toward disease susceptibility. PLoS Comput Biol 2010, 6(8):e1000910. 10.1371/journal.pcbi.1000910, 2928754, 20865155.
30. Mar JC, Matigian NA, Mackay-Sim A, Mellick GD, Sue CM, Silburn PA, McGrath JJ, Quackenbush J, Wells CA. Variance of gene expression identifies altered network constraints in neurological disease. PLoS Genet 2011, 7(8):e1002207. 10.1371/journal.pgen.1002207, 3154954, 21852951.
31. MacDonald JW, Ghosh D. COPA-cancer outlier profile analysis. Bioinformatics 2006, 22(23):2950-2951. 10.1093/bioinformatics/btl433, 16895932.
32. Tibshirani R, Hastie T. Outlier sums for differential gene expression analysis. Biostatistics 2007, 8(1):2-8. 10.1093/biostatistics/kxl005, 16702229.
33. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264. 10.1093/biostatistics/4.2.249, 12925520.
34. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98(1):31-36. 10.1073/pnas.98.1.31, 14539, 11134512.
35. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006, 7:278. 10.1186/1471-2164-7-278, 1636049, 17074082.
36. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics 2010, 11(2):242-253. 10.1093/biostatistics/kxp059, 2830579, 20097884.
37. McCall MN, Murakami PN, Lukk M, Huber W, Irizarry RA. Assessing affymetrix GeneChip microarray quality. BMC Bioinforma 2011, 12:137.
38. Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One 2009, 4(5):e5645. 10.1371/journal.pone.0005645, 2680989, 19461970.
39. Galamb O, Spisak S, Sipos F, Toth K, Solymosi N, Wichmann B, Krenacs T, Valcz G, Tulassay Z, Molnar B. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer 2010, 102(4):765-773. 10.1038/sj.bjc.6605515, 2837560, 20087348.
40. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007, 5(12):1263-1275. 10.1158/1541-7786.MCR-07-0267, 18171984.
41. Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning: data mining, inference, and prediction 2009, Springer, New York, NY, 2.
42. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30(1):207-210. 10.1093/nar/30.1.207, 99122, 11752295.
43. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007, 23(2):257-258. 10.1093/bioinformatics/btl567, 17098774.
44. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Pages -, ISSN (Online) 1544-6115.
45. McCall MN, Uppal K, Jaffee HA, Zilliox MJ, Irizarry RA. The Gene Expression Barcode: leveraging public data repositories to begin cataloging the human and murine transcriptomes. Nucleic Acids Res 2011, 39:D1011-D1015. Database issue, 10.1093/nar/gkq1259, 3013751, 21177656.
46. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536. 10.1038/415530a, 11823860.
47. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
48. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2010, 2(14):14ps2. 10.1126/scitranslmed.3000313, 20371465.
49. Fawcett T. An introduction to ROC analysis. Pattern Recogn Lett 2006, 27(8):861-874.
50. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44(3):837-845. 10.2307/2531595, 3203132.
51. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma 2011, 12:77.
52. Galamb O, Sipos F, Solymosi N, Spisak S, Krenacs T, Toth K, Tulassay Z, Molnar B. Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev 2008, 17(10):2835-2845. 10.1158/1055-9965.EPI-08-0231, 18843029.
53. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003, 100(16):9440-9445. 10.1073/pnas.1530509100, 170937, 12883005.